NEW YORK (GenomeWeb News) — Pharmacogenomics test developer MolecularMD has reeled in $3 million in financing from the Ballast Point Ventures, according to the St. Petersburg, Fla.-based venture capital firm.

MolecularMD is focused on developing molecular diagnostic tests to speed clinical development and regulatory approval of cancer therapies. The company's first tests were associated with imatinib (Gleevec), Novartis' treatment for chronic myelogenous leukemia, and it plans to expand into other cancer areas, including colon and lung cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.